Download presentation
Presentation is loading. Please wait.
Published bySusanti Kartawijaya Modified over 6 years ago
1
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial Frank Smithuis, MD, Moe Kyaw Kyaw, MBBS, Ohn Phe, BSc, Thein Win, MBBS, Pyay Phyo Aung, MBBS, Aung Pyay Phyo Oo, MBBS, Arkar Linn Naing, MBBS, Mya Yee Nyo, MBBS, Naing Zaw Htun Myint, MBBS, Mallika Imwong, PhD, Elizabeth Ashley, MRCP, Sue J Lee, PhD, Prof Nicholas J White, FRS The Lancet Infectious Diseases Volume 10, Issue 10, Pages (October 2010) DOI: /S (10) Copyright © 2010 Elsevier Ltd Terms and Conditions
2
Figure 1 Trial profile AA=artesunate–amodiaquine. PQ=primaquine. DP=dihydroartemisinin–piperaquine. AL=artemether–lumefantrine. AM-L=loose tablet regimen of artesunate–mefloquine. AM-F=fixed-dose artesunate–mefloquine. The Lancet Infectious Diseases , DOI: ( /S (10) ) Copyright © 2010 Elsevier Ltd Terms and Conditions
3
Figure 2 Comparative efficacy of the five ACT regimens against falciparum malaria in Myanmar Recurrences are recrudescence plus re-infections. AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=fixed-dose artesunate–mefloquine. AM-L=loose tablet regimen of artesunate–mefloquine. DP=dihydroartemisinin–piperaquine. The Lancet Infectious Diseases , DOI: ( /S (10) ) Copyright © 2010 Elsevier Ltd Terms and Conditions
4
Figure 3 Cumulative proportion of patients with vivax malaria during follow-up AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=fixed-dose artesunate–mefloquine. AM-L=loose tablet regimen of artesunate–mefloquine. DP=dihydroartemisinin–piperaquine. The Lancet Infectious Diseases , DOI: ( /S (10) ) Copyright © 2010 Elsevier Ltd Terms and Conditions
5
Figure 4 Effects of a single dose of primaquine on Plasmodium falciparum gametocyte carriage after artemisinin combination treatment All five ACT regimens pooled. No gametocytaemia was detected after day 42. The Lancet Infectious Diseases , DOI: ( /S (10) ) Copyright © 2010 Elsevier Ltd Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.